MESO Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

14.750

Open

14.720

VWAP

14.59

Vol

139.25K

Mkt Cap

1.91B

Low

14.515

Amount

2.03M

EV/EBITDA(TTM)

--

Total Shares

129.28M

EV

1.88B

EV/OCF(TTM)

--

P/S(TTM)

28.42

Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Show More

Events Timeline

(ET)

2026-04-15

08:50:00

Largest Indicative Borrow Rate Increases: Humacyte 16.96%

2026-04-14 (ET)

2026-04-14

21:40:00

Mesoblast Acquires Exclusive Worldwide License for CAR Technology

2026-04-08 (ET)

2026-04-08

05:30:00

Mesoblast Receives FDA Approval for Ryoncil Clinical Trial

2026-04-07 (ET)

2026-04-07

05:30:00

Mesoblast Ryoncil Net Sales Reach $30.3M in Q1

2026-04-06 (ET)

2026-04-06

21:10:00

Mesoblast Reports Ryoncil Net Sales of $30.3 Million

2026-03-30 (ET)

2026-03-30

08:50:00

Grabagun Digital Holdings Borrow Rate Increases to 5.85%

2026-03-12 (ET)

2026-03-12

08:50:00

KDK and Others See Significant Increases in Liquidity Borrow Rates

2026-01-28 (ET)

2026-01-28

08:50:00

Significant Increases in Indicative Borrow Rates for Liquid Options

2026-01-19 (ET)

2026-01-19

13:50:00

Mesoblast Submits FDA Feedback for rexlemestrocel-L Application

2026-01-02 (ET)

2026-01-02

05:10:00

Mesoblast Appoints Philip Facchina as New Non-Executive Chair

News

seekingalpha

04-30seekingalpha

Mesoblast Reports Strong Q1 Sales for Ryoncil®

Newsfilter

04-30Newsfilter

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial

Yahoo Finance

04-30Yahoo Finance

Mesoblast Achieves Patient Recruitment Target in Chronic Low Back Pain Trial

moomoo

Mesoblast Announces RYONCIL® Net Revenues of $30.3 Million and Reduced Net Operating Cash Expenditure of $4.1 Million for the Quarter

NASDAQ.COM

04-29NASDAQ.COM

Mesoblast Completes Patient Recruitment for Chronic Low Back Pain Trial

Newsfilter

04-29Newsfilter

Mesoblast Completes Patient Recruitment for Chronic Low Back Pain Trial

1 Analyst Rating

Wall Street analysts forecast MESO stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

35.00

Averages

35.00

High

35.00

Current: 0.000

Low

35.00

Averages

35.00

High

35.00

Jefferies

Hold

to

Buy

upgrade

$3

AI Analysis

2025-11-25

Reason

Jefferies

Price Target

$3

AI Analysis

2025-11-25

upgrade

Hold

to

Buy

Reason

Jefferies upgraded Mesoblast to Buy from Hold with a price target of A$3.30, up from A$3.

Jefferies

David Stanton

Hold

to

Buy

upgrade

$3

2025-11-25

Reason

Jefferies

David Stanton

Price Target

$3

2025-11-25

upgrade

Hold

to

Buy

Reason

As previously reported, Jefferies analyst David Stanton upgraded Mesoblast to Buy from Hold with a price target of A$3.30, up from A$3. Ryoncil continues to be rolled out and the firm forecasts 78 patients will complete therapy in FY26, up from 63, while updating its estimates for fiscal Q2 results and FY26 forecasts.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MESO

Unlock Now

Valuation Metrics

The current forward P/E ratio for Mesoblast Ltd (MESO.O) is 454.55, compared to its 5-year average forward P/E of 15.95. For a more detailed relative valuation and DCF analysis to assess Mesoblast Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

15.95

Current PE

454.55

Overvalued PE

150.20

Undervalued PE

-118.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-3.57

Current EV/EBITDA

-11.48

Overvalued EV/EBITDA

92.19

Undervalued EV/EBITDA

-99.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

28.00

Current PS

6.23

Overvalued PS

45.67

Undervalued PS

10.32

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

most profit u.s. stock tomorrow

Intellectia · 3 candidates

Region: USPrice: $10.00 - $200.00Relative Vol: >= 1.30List Exchange: XNYS, XNAS, XASEOne Day Rise Prob: >= 75One Day Predict Return: >= 2.0%Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Nike Inc

63.22B

Gaming and Leisure Properties Inc

13.01B

Mesoblast Ltd

1.76B

top moving stocks

Intellectia · 31 candidates

Market Cap: >= 500.00MPrice: >= $2.00Price Change Pct: $-100.00 - $-5.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Lindsay Corp

1.22B

Knife River Corp

4.65B

Omeros Corp

869.71M

Wix.Com Ltd

5.28B

Ironwood Pharmaceuticals Inc

635.93M

Prestige Consumer Healthcare Inc

2.73B

top stocks to daytrade tomorrow

Intellectia · 18 candidates

Sector: Academic & Educational Services, Applied Resources, Automobiles & Auto Parts, Basic Materials, Banking & Investment Services, Chemicals, Collective Investments, Consumer Cyclicals, Consumer Goods Conglomerates, Consumer Non-Cyclicals, Cyclical Consumer Services, Cyclical Consumer Products, Energy, Energy - Fossil Fuels, Financials, Financial Technology (Fintech) & Infrastructure, Food & Beverages, Food & Drug Retailing, Government Activity, Healthcare, Healthcare Services & Equipment, Industrials, Investment Holding Companies, Industrial & Commercial Services, Industrial Goods, Insurance, Mineral Resources, Pharmaceuticals & Medical Research, Personal & Household Products & Services, Real Estate, Retailers, Renewable Energy, Software & IT Services, Technology, Technology Equipment, Telecommunications Services, Transportation, Uranium, UtilitiesPrice: $5.00 - $100.00Price Change Pct: $3.00 - $15.00Relative Vol: >= 1.50Beta: HighRiskList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Kyndryl Holdings Inc

2.54B

ON Semiconductor Corp

26.55B

James Hardie Industries PLC

14.14B

Klaviyo Inc

6.38B

Yext Inc

687.94M

MakeMyTrip Ltd

5.91B

what is the best day trade of today?

Intellectia · 53 candidates

Price: $5.00 - $100.00Price Change Pct: $4.00 - $20.00Relative Vol: >= 2One Day Predict Return: >= 0.0%Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Avalo Therapeutics Inc

257.14M

Townsquare Media Inc

118.19M

Celanese Corp

6.39B

Mesoblast Ltd

2.32B

SMX (Security Matters) PLC

171.43M

Dream Finders Homes Inc

1.95B

Whales Holding MESO

Trading Trends

People Also Watch

Frequently Asked Questions

What is Mesoblast Ltd (MESO) stock price today?

The current price of MESO is 14.51 USD — it has decreased -1.56

What is Mesoblast Ltd (MESO)'s business?

Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

What is the price predicton of MESO Stock?

Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is35.00 USD with a low forecast of 35.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Mesoblast Ltd (MESO)'s revenue for the last quarter?

Mesoblast Ltd revenue for the last quarter amounts to NaN USD, decreased

What is Mesoblast Ltd (MESO)'s earnings per share (EPS) for the last quarter?

Mesoblast Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Mesoblast Ltd (MESO). have?

Mesoblast Ltd (MESO) has 81 emplpoyees as of May 12 2026.

What is Mesoblast Ltd (MESO) market cap?

Today MESO has the market capitalization of 1.91B USD.